Predicting Breast Tumor Response to Neoadjuvant Chemotherapy with Diffuse Optical Spectroscopic Tomography prior to Treatment
Lists
Only you see this
Abstract
This is the first clinical evidence that DOST HbT may differentiate the two groups with predictive significance based on data acquired before NAC even begins. The study also demonstrates the potential of accelerating the validation of optimal NAC regimens through future randomized clinical trials by reducing the number of patients required and the length of time they need to be followed by using a validated imaging surrogate as an outcome measure.
BibTeX
@inproceedings{jiang2014predicting,
author = {Shudong Jiang and Brian W. Pogue and Peter A. Kaufman and Jiang Gui and Michael Jermyn and Tracy E. Frazee and Steven P. Poplack and Roberta M. diFlorio‐Alexander and Wendy A. Wells and Keith D. Paulsen},
title = {{Predicting Breast Tumor Response to Neoadjuvant Chemotherapy with Diffuse Optical Spectroscopic Tomography prior to Treatment}},
booktitle = {Clinical},
year = {2014},
doi = {10.1158/1078-0432.ccr-14-1415},
}Loading related content...